Physician profile
Robin Jacob
NPI 1962652487
$34,021.08
in general payments reported to CMS, 2019-2025
35 companies · $700 in 2025
The $700 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,370 · 2020: $1,400 · 2021: $4,455 · 2022: $4,936 · 2023: $7,644 · 2024: $6,516 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,908 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,060 · Food and Beverage: $1,733 · Travel and Lodging: $1,097 · Education: $62.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,907.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,060.00 |
| Food and Beverage | $1,732.78 |
| Travel and Lodging | $1,097.47 |
| Education | $62.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $8,816.56 | 2023-2024 | Zanidatamab |
| Incyte Corporation | $8,726.98 | 2020-2022 | |
| Amgen INC. | $4,543.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $3,051.23 | 2023-2025 | Imfinzi, Lynparza, Tagrisso |
| Exelixis INC. | $2,050.97 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,725.85 | 2019 | |
| Beigene USA, INC. | $1,666.94 | 2023-2024 | Brukinsa |
| Abbott Laboratories | $550.88 | 2022-2025 | Optis, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Beigene, LTD. | $525.00 | 2021 | |
| Astellas Pharma US INC | $500.00 | 2021 | |
| Emd Serono, INC. | $500.00 | 2021 | |
| Acist Medical Systems, INC. | $346.34 | 2022-2023 | |
| Glaxosmithkline, LLC. | $125.00 | 2021 | |
| Janssen Biotech, INC. | $92.06 | 2024-2025 | Rybrevant, Erleada, Akeega |
| Tempus Ai, INC | $77.22 | 2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $70.19 | 2019-2023 | Opdivo |
| Merck Sharp & Dohme LLC | $66.08 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Gilead Sciences, INC. | $60.61 | 2021-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $60.20 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $59.88 | 2023-2025 | Fotivda |
| Daiichi Sankyo INC. | $51.41 | 2024-2025 | Enhertu, Datroway |
| Celgene Corporation | $50.26 | 2024-2025 | Reblozyl, Pomalyst |
| Mirati Therapeutics, INC. | $42.00 | 2023 | Krazati |
| Pfizer INC. | $38.42 | 2019-2025 | |
| Array Biopharma INC | $29.58 | 2025 | Mektovi, Tukysa, Braftovi |
| Regeneron Healthcare Solutions, INC. | $26.53 | 2024 | Libtayo |
| Blue Earth Diagnostics | $25.05 | 2019 | |
| Taiho Oncology, INC. | $24.34 | 2025 | |
| Sumitomo Pharma America, INC. | $22.72 | 2025 | Orgovyx |
| Biocompatibles, INC. | $19.54 | 2019 | |
| Lilly USA, LLC | $17.93 | 2020 | |
| Ucb, INC. | $17.64 | 2025 | Fintepla |
| Kite Pharma, INC. | $14.89 | 2020 | |
| Cti Biopharma Corp. | $14.33 | 2022 | |
| Genentech USA, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.